Tissue cross-reactivity studies of CPGJ701 in humans, cynomolgus monkeys and Sprague-Dawley rats and correlation analysis with in vivo toxicity | Zendy

Zhe Qu | Zendy; Jianjun Lyu | Zendy; Yue Liu | Zendy; Xin Wang | Zendy; Zhi Lin | Zendy; Yanwei Yang | Zendy; Di Zhang | Zendy; Xingchao Geng | Zendy; Bo Li | Zendy

Open Access

Tissue cross-reactivity studies of CPGJ701 in humans, cynomolgus monkeys and Sprague-Dawley rats and correlation analysis with in vivo toxicity

Author(s) -

Zhe Qu,

Jianjun Lyu,

Yue Liu,

Xin Wang,

Zhi Lin,

Yanwei Yang,

Di Zhang,

Xingchao Geng,

Bo Li

Publication year - 2020

Publication title -

annals of translational medicine

Language(s) - English

Resource type - Journals

eISSN - 2305-5847

pISSN - 2305-5839

DOI - 10.21037/atm.2020.02.106

Subject(s) - immunohistochemistry , in vivo , antibody , toxicity , pathology , ex vivo , monoclonal antibody , kidney , biology , medicine , immunology , microbiology and biotechnology

The TCR of CPGJ701 was in accord with the targeting characteristics of the humanized anti-HER2 monoclonal antibody. The consistency of CPGJ701 binding to human and cynomolgus monkey tissues indicated that the cynomolgus monkey is a relevant animal species for evaluating the preclinical safety of CPGJ701. The targeting (binding site) of CPGJ701 in Sprague-Dawley rats indicated that it is also a useful animal species for evaluating antibody-dependent toxicity and non-antibody-dependent toxicity. In conclusion, these TCR studies of CPGJ701 could provide information for selecting relevant animal species for nonclinical studies and predicting clinical ADRs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research